Clinical Trials Directory

Trials / Unknown

UnknownNCT00930735

The Prognostic Significance of Fibrosis Detection in Cardiomyopathy

The Prognostic Significance of Fibrosis Detection in Ischemic and Non-ischemic Cardiomyopathy

Status
Unknown
Phase
Study type
Observational
Enrollment
3,000 (estimated)
Sponsor
Royal Brompton & Harefield NHS Foundation Trust · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The presence of scar within heart muscle can act as a substrate for abnormal rhythm problems and lead to the developement of heart failure Clinical significance Correlation with biomarkers and genetic markers

Detailed description

Patients will undergo cardiovascular magnetic resonance (CMR) to include measurement of left ventricular volumes, ejection fraction, detection of inflammation (via STIR sequences) where appropriate, early gadolinium enhancement, late gadolinium enhancement, first pass perfusion using pharmacological stress imaging (contraindications to include comorbidities that do not permit pharmacological stress agents e.g. severe asthma, severe or symptomatic aortic stenosis)

Conditions

Timeline

Start date
2000-01-01
Primary completion
2020-04-30
Completion
2025-07-01
First posted
2009-06-30
Last updated
2018-04-23

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT00930735. Inclusion in this directory is not an endorsement.